Study to determine serum and skin biopsy biomarkers in patients receiving topical corticosteroid (TCS) and following TCS withdrawal (GNE-AD)

Sponsor: Genentech, Inc.

Location(s): United States


The purpose of this study is to assess the differential expression of Atopic Dermatitis (AD) biomarkers in serum, plasma, and skin biopsies from both lesional and non-lesional skin in moderate to severe AD patients in the presence of Topical Corticosteroid (TCS) and after withdrawal from TCS.

This exploratory study consists of four visits to the investigator site post screening: at Weeks 0 (baseline), 2, 6 and 8. At the first visit (baseline), patients who have met the screening eligibility criteria will be started on a stable TCS regimen for a total of two weeks. At the second visit (Week 6) following two weeks of therapy on stable TCS, patients will stop TCS and blood, serum, plasma and two 6mm punch biopsies (one lesional (L) and one non-lesional (NL) skin) will be obtained. At the third visit (Week 6), after four weeks receiving no TCS, the same sample collections will be repeated and the patients will then enter a two week safety follow up. At the end of the safety follow up (last visit, Week 8) and after obtaining written informed consent by the patient, blood, serum and plasma samples mav be collected.